Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...
such as chimeric antigen receptor–NK cell treatment. Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have ...
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia ... it from the very different disease of chronic lymphocytic leukemia, which has a potential time course ...
chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) reveal that a changed score of −11/+11 for symptom burden, −16/+16 for physical condition/fatigue and −16/+13 for ...
BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced its new partnership with CLL Society, the world's leading authority for chronic ...
Results from a clinical trial ... Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec. 5, 2024 — The first comprehensive map of the dramatic changes that take ...
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of 10 abstracts for poster presentations and two abstracts for online publication at ...